The vehicle-treated anti-GBM-GN mice exhibited activation of the PI3k/Akt and MAPK signaling pathways in the kidneys as evidenced by significant increase in the p-Akt, p-JNK, p-ERK1/2, and p-P38 levels (Fig. 6). The gene discussed is AKT1; the disease is glioblastoma.